PE20040468A1 - ORGANIC COMPOUND COMBINATION - Google Patents

ORGANIC COMPOUND COMBINATION

Info

Publication number
PE20040468A1
PE20040468A1 PE2003000471A PE2003000471A PE20040468A1 PE 20040468 A1 PE20040468 A1 PE 20040468A1 PE 2003000471 A PE2003000471 A PE 2003000471A PE 2003000471 A PE2003000471 A PE 2003000471A PE 20040468 A1 PE20040468 A1 PE 20040468A1
Authority
PE
Peru
Prior art keywords
salt consisting
organic compound
compound combination
composition
ethachrinic
Prior art date
Application number
PE2003000471A
Other languages
Spanish (es)
Inventor
Melissa Grigorieff
Randy Lee Webb
Suraj Shivappa Shetty
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20040468A1 publication Critical patent/PE20040468A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN INHIBIDOR DE LA ENZIMA CONVERTIDORA DE ANGIOTENSINA O UNA SAL QUE CONSISTE EN ALACEPRIL, BENAZEPRIL, CAPTOPRIL, ENTRE OTROS; B) UN BLOQUEADOR DE CANAL DE CALCIO (CCB), O UNA SAL QUE CONSISTE EN AMLODIPINA, FELODIPINA, NIGULDIPINA, ENTRE OTROS; C) UN DIURETICO O UNA SAL QUE CONSISTE EN BUMETANIDA, ACIDO ETACRINICO, FUROSEMIDA, ENTRE OTROS. DICHA COMPOSICION ES UTIL EN HIPERTENSION, CONDICIONES DE INSUFICIENCIA RENAL Y MANEJO DE OTROS DESORDENES VASCULARESIT REFERS TO A PHARMACEUTICAL COMPOSITION THAT INCLUDES: A) AN INHIBITOR OF ANGIOTENSIN CONVERTER ENZYME OR A SALT CONSISTING OF ALACEPRIL, BENAZEPRIL, CAPTOPRIL, AMONG OTHERS; B) A CALCIUM CHANNEL BLOCKER (CCB), OR A SALT CONSISTING OF AMLODIPINE, FELODIPINE, NIGULDIPINE, AMONG OTHERS; C) A DIURETIC OR A SALT CONSISTING OF BUMETANIDE, ETHACHRINIC ACID, FUROSEMIDE, AMONG OTHERS. SUCH COMPOSITION IS USEFUL IN HYPERTENSION, KIDNEY INSUFFICIENCY CONDITIONS AND MANAGEMENT OF OTHER VASCULAR DISORDERS

PE2003000471A 2002-05-17 2003-05-15 ORGANIC COMPOUND COMBINATION PE20040468A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38154502P 2002-05-17 2002-05-17

Publications (1)

Publication Number Publication Date
PE20040468A1 true PE20040468A1 (en) 2004-09-14

Family

ID=29550140

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000471A PE20040468A1 (en) 2002-05-17 2003-05-15 ORGANIC COMPOUND COMBINATION

Country Status (9)

Country Link
US (1) US20040254176A1 (en)
EP (1) EP1507537A1 (en)
JP (1) JP2005526130A (en)
AR (1) AR040017A1 (en)
AU (1) AU2003232791A1 (en)
CA (1) CA2482348A1 (en)
PE (1) PE20040468A1 (en)
TW (1) TW200306799A (en)
WO (1) WO2003097067A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040198789A1 (en) * 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations
WO2004110354A2 (en) 2003-05-15 2004-12-23 Roskamp Research, Llc Method for reducing amyloid deposition, amyloid neurotoxicity and microgliosis
ES2322854T3 (en) * 2003-06-26 2009-06-30 Teva Pharmaceutical Industries Limited STABLE PHARMACEUTICAL COMPOSITIONS OF ACID DERIVATIVES 2-AZA-BICICLO (3.3.0) -OCTANO-3-CARBOXILICO.
JPWO2005011736A1 (en) * 2003-07-30 2006-09-14 株式会社 東北テクノアーチ Preventive and / or therapeutic agent for Alzheimer's disease
JP2007504135A (en) * 2003-08-28 2007-03-01 ニトロメッド インコーポレーティッド Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
RU2006117198A (en) * 2003-10-20 2007-12-10 Новартис АГ (CH) APPLICATION OF ORGANIC COMPOUNDS
PL1687006T3 (en) 2003-11-18 2008-01-31 Solvay Pharm Gmbh Pharmaceutical compositions for the treatment of renal dysfunction
DE102004011512B4 (en) 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical preparation containing pimobendan
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1579862A1 (en) * 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US20060034913A1 (en) * 2004-08-13 2006-02-16 James Gaede Multiplex drug delivery device
EP1855688A4 (en) * 2005-02-24 2011-09-14 Nicox Sa Nitric oxide enhancing diuretic compounds, compositions and methods of use
ATE526965T1 (en) 2005-04-15 2011-10-15 Res & Innovation S P A METHOD FOR PREVENTING, DELAYING OR REVERSING ABNORMAL AMYLOID DEPOSIT
GB0520405D0 (en) * 2005-10-07 2005-11-16 Imp College Innovations Ltd Biological agents and method
EP1948136A1 (en) * 2005-11-07 2008-07-30 King Pharmaceuticals Research and Development, Inc. Compositions of stabilized ramipril in combination with another active agent
KR20080112387A (en) * 2006-04-19 2008-12-24 테바 파마슈티컬 인더스트리즈 리미티드 Stable pharmaceutical composition of 2-aza-bicyclo [3.3.0] -octane-3-carboxylic acid derivatives
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
ES2449594T3 (en) 2007-10-05 2014-03-20 Alzheimer's Institute Of America, Inc. Method to reduce amyloid deposition, amyloid neurotoxicity and microgliosis with enantiomer (-) - nilvadipine
US20100137403A1 (en) * 2008-07-10 2010-06-03 Scott Malstrom Method for enhancing cognition or inhibiting cognitive decline
CN101669957B (en) * 2008-09-09 2012-06-13 深圳信立泰药业股份有限公司 Pharmaceutical composition of lercanidpine and benazepril and application thereof
DE102008059206A1 (en) 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmaceutical dosage form containing nifedipine or nisoldipine and an angiotensin II antagonist and / or a diuretic
IT1398168B1 (en) * 2010-02-16 2013-02-14 Chiesi Farma Spa USE OF ACTIVE INGREDIENTS IN COMBINATION FOR THE TREATMENT OF COMPLICATIONS OF DIABETES.
SI2585051T2 (en) 2010-06-23 2020-07-31 Krka, D.D., Novo Mesto Pharmaceutical oral dosage forms comprising lercanidipine and enalapril and their pharmaceutically acceptable salts
ES2924478T3 (en) 2012-03-15 2022-10-07 Boehringer Ingelheim Vetmedica Gmbh Formulation of pharmaceutical tablets for the veterinary medical sector, method of production and use thereof
PL3021832T3 (en) 2013-07-19 2021-08-23 Boehringer Ingelheim Vetmedica Gmbh PRESERVED LIQUID AQUEOUS PHARMACEUTICAL COMPOSITION CONTAINING ETERIFICATED CYCLODEXTRIN DERIVATIVES
PH12016500358B1 (en) * 2013-08-23 2023-08-16 Reata Pharmaceuticals Inc Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
BR122019024673B1 (en) 2013-12-04 2023-04-11 Boehringer Ingelheim Vetmedica Gmbh IMPROVED PHARMACEUTICAL COMPOSITIONS OF PIMOBENDAN
WO2015153379A1 (en) * 2014-04-01 2015-10-08 Ailex Pharmaceuticals, Pvt. Ltd. Fiixed dosage formulations of angiotensin converting enzyme (ace) inhibitor and the diuretic chlorthalidone
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
BR112022021011A2 (en) * 2020-04-17 2022-12-27 Honeybrains Llc COMPOSITIONS AND METHODS FOR TREATMENT OF NEUROPSYCHIATRIC DISORDERS
GB202006819D0 (en) * 2020-05-07 2020-06-24 Closed Loop Medicine Ltd Dosage regimen
GR1010675B (en) * 2023-02-17 2024-04-23 Ιουλια Κλεωνος Τσετη Orally administrated anti-hypertension drug composed of a triple combination of an ace inhibitor, a calcium antagonist and a diuretic composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100222252B1 (en) * 1990-12-14 1999-10-01 스튜어트 알. 수터 Angiotensin II Receptor Blocking Composition
MX9706957A (en) * 1995-03-16 1997-11-29 Pfizer Composition containing amlodipine, or a salt or felodipine and anace inhibitor.
EP0795327A1 (en) * 1996-03-13 1997-09-17 Pfizer Inc. Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin
US6632180B1 (en) * 2000-09-07 2003-10-14 John H. Laragh Method for evaluating and treating hypertension

Also Published As

Publication number Publication date
CA2482348A1 (en) 2003-11-27
AU2003232791A1 (en) 2003-12-02
TW200306799A (en) 2003-12-01
EP1507537A1 (en) 2005-02-23
AR040017A1 (en) 2005-03-09
WO2003097067A1 (en) 2003-11-27
US20040254176A1 (en) 2004-12-16
JP2005526130A (en) 2005-09-02

Similar Documents

Publication Publication Date Title
PE20040468A1 (en) ORGANIC COMPOUND COMBINATION
PE20040439A1 (en) ORGANIC COMPOUND COMBINATION
EP1575566A4 (en) MULTILAYER GALENIC FORMS CONTAINING NSAIDS AND TRIPTANES
Tanaka et al. Effects of prothrombin complex concentrate and recombinant activated factor VII on vitamin K antagonist induced anticoagulation
Hegde et al. Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat
PE107099A1 (en) COMPOSITION OF ATORVASTATINE AND AN ANTI-HYPERTENSOR
ATE273305T1 (en) THROMBIN INHIBITORS
PE20070420A1 (en) FORMULATION CONTAINING A COMBINATION OF VALSARTAN AND AMLODIPINE
EA200400966A1 (en) NEW MEDICATED FORMS OF SUBSTITUTED BENZIMIDAZOL AND METHOD OF THEIR APPLICATION
DE59911670D1 (en) Glutamine thiazolidides and pyrrolidides and their use as dipeptidyl peptidase IV inhibitors
TR200100149T2 (en) Biphenyl-sulfonamides as dual angiotensin endothelin receptor antagonists
EA199800873A1 (en) ESPROSARTANA DIHYDRATE AND METHOD FOR ITS PREPARATION AND PREPARED PREPARATION FORM
EE200000499A (en) Prolonged-release preparation with angiotensin II antagonist activity, method of preparation and use
WO2003106967A3 (en) Method of evaluating myelosuppressive state
CL2004000366A1 (en) USE OF A COMBINATION OF A QUINASA P38 INHIBITING DERIVED COMPOUND OF PIRAZOL, AND AN ACE INHIBITOR TO TREAT RENAL DYSFUNCTION, CARDIOVASCULAR AND VASCULAR DISEASE, RETINOPATHY, NEUROPATIA, EDOTEL, INSOTUNATIO OPINION.
MA31454B1 (en) MODULATORS OF KALLIKREIN 7
PE20000266A1 (en) PROCEDURE TO TREAT HEART FAILURE
BRPI0504445A (en) thrombin composition and process for its preparation
PE20060594A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING A PPAR AGONIST
TNSN04138A1 (en) (3 - {[4-TERTIOBUTYLBENZYL] - (PYRIDINE-3-SULFONYL) -AMINO] -METHYL} -PHENOXY) -ACETIC ACID METABOLITES
ES2182334T3 (en) EPROSARTAN MONOHIDRATE.
TR200001412T2 (en) Oral dosage formulations containing a large amount of drugs, providing an immediate and modified release, and the process for making them.
PE20040774A1 (en) COMBINATION OF AN INHIBITOR OF FACTOR Xa AND CLOPIDOGREL
NO20061033L (en) Compositions and Methods for Delivery of Biologically Active Agents
Kucharewicz et al. The antithrombotic effect of angiotensin-(1—7) closely resembles that of losartan

Legal Events

Date Code Title Description
FC Refusal